Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 5INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Gastrointestinal 3Genitourinary 2Sarcoma 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Leiomyosarcoma 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × cixutumumab × Sarcoma × Clear all
NCT00668148 2018-07-17

A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Eli Lilly and Company

Phase 2 Completed
113 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡